Curis Inc (NAS:CRIS)
$ 3.96 -0.18 (-4.35%) Market Cap: 35.05 Mil Enterprise Value: 15.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Curis Inc at Needham Healthcare Conference (Virtual) - On-Demand Transcript

Apr 12, 2022 / 12:45PM GMT
Release Date Price: $26.2 (-0.76%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning, and welcome to day 2 of the Annual Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today Curis' CEO, Jim Dentzer. (Conference Instructions)

And with that, Jim, you have the stage.

Jim Dentzer
Curis, Inc. - President & CEO

Thank you, Gil, really appreciate it. Thank you for having us here today. I really appreciate the chance to talk about Curis. I have our corporate deck up. I'm not going to belabor every slide, but I'm going to hit through some of the high points. I think what we've got going on is really unique and compelling.

So first, what makes Curis different from other biotech companies is that we look to develop exclusively novel, first-in-class, cancer drugs. There are no me-too drugs at Curis. In addition, we take an approach where we are pursuing drugs that we believe have a significant potential in terms of unmet need. What does that mean? It means

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot